Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

636
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
636
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.9K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coronary intimal proliferation despite lipid reduction during the first year after heart transplantation.

Heart and vessels·2026
Same author

Homozygous SGCB splice-site variant causes isolated dilated cardiomyopathy through sarcoglycan complex destabilization in East Asians.

The Journal of clinical investigation·2026
Same author

Elevated serum agalactosyl IgG is associated with higher inferior vena cava pressure in patients with adult congenital heart disease.

Journal of cardiology·2026
Same author

PCPE-1 promotes cardiac fibrosis with aging and obesity.

JCI insight·2026
Same author

A Case of Primary Malignant Melanoma of the Nasolacrimal Duct.

Cureus·2026
Same author

Usefulness and safety of salvage surgery with reconstruction for recurrent head and neck cancer with a history of reconstruction surgery and radiation therapy.

Surgical oncology·2025

Related Experiment Video

Updated: Mar 18, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.8K

Btg2 is a Negative Regulator of Cardiomyocyte Hypertrophy through a Decrease in Cytosolic RNA.

Yuki Masumura1, Shuichiro Higo1, Yoshihiro Asano1

  • 1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.

Scientific Reports
|June 28, 2016
PubMed
Summary

Cardiomyocyte growth involves RNA changes. Researchers found c-Myc boosts RNA production, while Btg2 suppresses it, revealing new mechanisms in heart hypertrophy.

More Related Videos

Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy
06:51

Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy

Published on: May 21, 2014

48.9K
Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
10:05

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5

Published on: November 13, 2015

9.2K

Related Experiment Videos

Last Updated: Mar 18, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.8K
Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy
06:51

Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy

Published on: May 21, 2014

48.9K
Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
10:05

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5

Published on: November 13, 2015

9.2K

Area of Science:

  • Molecular and Cellular Biology
  • Cardiovascular Research
  • Gene Regulation

Background:

  • Cardiomyocytes increase RNA during hypertrophic stimulation, entering a hypermetabolic state.
  • Mechanisms regulating RNA accumulation and functional implications in cardiomyocytes are not well understood.
  • Protein regulation pathways are well-studied, but RNA dynamics remain elusive.

Purpose of the Study:

  • To elucidate the quantitative kinetics of RNA in cardiomyocytes.
  • To investigate the role of c-Myc (Myc) in regulating RNA production.
  • To identify novel targets of Myc and their function in cardiomyocyte hypertrophy.

Main Methods:

  • Single-cell imaging with nascent RNA labeling.
  • Chromatin immunoprecipitation with high-throughput sequencing (ChIP-seq).
  • Mass spectrometry to identify protein interactions.
  • Overexpression and knockdown studies (shRNA) of target genes.

Main Results:

  • c-Myc significantly increased global RNA production in cardiomyocytes.
  • Myc binds specific genes, recruiting RNA polymerase II; Btg2 identified as a novel Myc target.
  • Btg2 overexpression reduced cardiomyocyte size; Btg2 knockdown accelerated hypertrophy.
  • Btg2 interacts with mRNA deadenylation complexes and suppresses cytosolic RNA levels.

Conclusions:

  • Btg2 negatively regulates reactive hypertrophy by suppressing cytosolic RNA accumulation.
  • Btg2 knockdown enhances RNA accumulation during adrenergic stimulation.
  • Findings provide insight into RNA regulation mechanisms and their functional significance in cardiomyocytes.